Elevance Health, Inc. Material Event - Investor Summary

Elevance Health, Inc. (formerly Anthem, Inc.), a leading health insurance provider, recently faced a significant regulatory challenge that could impact its Medicare Advantage business. This summary breaks down the key information for investors from its recent SEC filing.

---

1. Event Description

The Centers for Medicare & Medicaid Services (CMS) recently notified Elevance Health of proposed sanctions. CMS plans to suspend new enrollments into Elevance Health's Medicare Advantage-Prescription Drug (MA-PD) plans and prohibit certain marketing and communication activities targeting prospective new Medicare members.

CMS alleges Elevance Health failed to comply with specific rules for submitting "risk adjustment data" for its Medicare Advantage plans. This data, which reflects members' health status, helps CMS accurately determine payments to insurance providers. The alleged non-compliance involves services provided before April 3, 2023.

Elevance Health states it revised its practices in April 2023, following new CMS guidelines. The company believes it has already addressed the underlying issues that led to these allegations.

2. Event Date/Timeline

Elevance Health received CMS's notification on February 27, 2026. The proposed sanctions will become effective on March 31, 2026, unless Elevance Health resolves the underlying issues to CMS's satisfaction beforehand. The alleged non-compliance with risk adjustment data submission rules relates to services provided before April 3, 2023. Elevance Health revised its practices in April 2023.

3. Impact Assessment (Operational & Stakeholder Impact)

This development is critical because Medicare Advantage drives significant growth and revenue for Elevance Health. Temporarily halting new enrollments directly impacts:

• Revenue Growth: Halting new enrollments will curb a key business segment's expansion, potentially affecting future revenue projections.
• Market Share: Elevance Health could lose market share in the highly competitive Medicare Advantage landscape, as competitors may capture members it cannot enroll.
• Reputational Risk: Regulatory actions can erode trust among members, providers, and investors, potentially leading to increased scrutiny.

Stakeholder Impact:

• Investors: Expect increased stock price volatility in the short term as the market assesses the duration and financial impact of these potential sanctions. The company's lack of specific financial impact estimates adds to uncertainty.
• Current MA-PD Members: Elevance Health confirms the proposed suspension does NOT impact current Medicare Advantage-Prescription Drug (MA-PD) members' benefits or plans. Their coverage remains unchanged.
• Potential New Customers: Individuals seeking to enroll in an Elevance Health MA-PD plan after March 31, 2026, would need to seek coverage from other providers if the sanctions take effect.
• Competitors: Other health insurers offering Medicare Advantage plans may gain market share if Elevance Health cannot enroll new members.

4. Financial Impact

If implemented, the proposed sanctions will directly impact Elevance Health's revenue growth by halting new enrollments in a key business segment. Additionally, CMS's allegations of risk adjustment data non-compliance could lead to significant financial exposure through the recoupment of past payments. This means CMS might demand Elevance Health return funds it previously received based on the allegedly incorrect data.

While Elevance Health acknowledges these potential impacts, its 8-K filing did not estimate the potential financial recoupment or its impact on earnings. The company has not yet provided updated financial guidance or estimated the quantitative impact on its full-year earnings per share (EPS) or revenue. The full financial impact will remain unclear until CMS resolves its allegations and determines the final outcome of any sanctions or recoupment efforts.

5. Company Response and Outlook

Elevance Health is actively engaging with CMS to cooperatively address these concerns. Their primary goal is to demonstrate that they have "satisfactorily addressed" the issues before March 31, 2026, preventing the sanctions from taking effect.

6. Key Takeaways for Investors

• Financial Impact is Key: Investors' most significant unknown is the magnitude of potential financial recoupment by CMS for past risk adjustment data issues, alongside the revenue impact from lost new enrollments. This information is critical for valuation.
• Resolution Timeline: The speed and success of Elevance Health's negotiations with CMS are paramount. A swift resolution before March 31, 2026, would significantly mitigate the impact.
• Long-Term Strategy: Investors should evaluate how this event affects Elevance Health's long-term growth strategy in the Medicare Advantage market and its ability to navigate complex regulatory environments.
• Guidance Revision: Watch for any updates to Elevance Health's financial guidance, as this will provide the most concrete indication of management's expected impact.

This situation underscores the significant regulatory risks inherent in the highly regulated healthcare insurance industry. Investors should conduct thorough due diligence and closely monitor official company and CMS announcements.